Can the formula be customized?

Yes, the function can be customized as Vitamin Additives to suit specific needs.

Mixed Feed Additive King Vc Improve Liver Function

Name: Mixed Feed Additive King Vc Improve Liver Function
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1979702872

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$6.00-10.00

500 Bags

Sample price:US$9.00/kg.Request sample

Product profile

Customization

Available

Certification

ISO

Shape

Powder

Model NO.

Type

Vitamin

Function

Vitamin Additives

Transport Package

1kg/Bag

Trademark

Moosun

Origin

China

HS Code

2309901000

Production Capacity

500tons/Month

Key features

Liver Protection & Detox: Protects liver function and assists detoxification against arsenic, mercury, and lead poisoning.

Heat Stress Relief: Improves stress response from high temperature and humidity, reducing anorexia and dehydration.

Behavior Stabilization: Reduces restlessness, fighting, tail biting, and abnormal behaviors during long-distance transport.

Nutrient Replenishment: Replaces lost salt and nutrients due to excessive water intake in summer, improving physical condition.

Antibody Promotion: Promotes antibody formation and protects enzyme systems from poison damage via sulfhydryl groups.

Customizable Formula: Function is customizable as Vitamin Additives to meet specific animal health requirements.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤11.20h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.